Key Drivers
- Strong Profitability
- High Leverage
- Negative Equity
AIAI Summary
ABBV's post-Humira transition is succeeding, but the stock now hinges on Skyrizi/Rinvoq sustaining exceptional growth while neuroscience diversifies the earnings base; with limited valuation upside and high leverage, investors should hold or accumulate only on evidence of continued immunology outperformance and deleveraging.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •High Leverage
- •Negative Equity
ABBV delivers strong margins and cash flow, but elevated leverage, negative equity, weak working capital, and premium valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Strong rebound
- •Key resistance
- •Support holding
ABBV is cautiously constructive after rebounding from $248.78–$250 support last month, but a decisive break above $264–$266 resistance is needed to sustain upside.
Sharp recovery from the
Sentiment & News
Key News Insights:
- •Post-Humira Transition
- •Pipeline Expansion
- •Institutional Buying
AbbVie's growth outlook is increasingly supported by Skyrizi, Rinvoq and pipeline expansion, though Humira erosion and near-term acquisition dilution remain risks.
The news is broadly positive for AbbVie, with diversified growth drivers helping offset Humira-related pressure
Similar Companies in Healthcare
Other companies in the same sector with AI ratings